PMID- 26543085
OWN - NLM
STAT- MEDLINE
DCOM- 20160912
LR  - 20220321
IS  - 1790-6245 (Electronic)
IS  - 1109-6535 (Linking)
VI  - 12
IP  - 6
DP  - 2015 Nov-Dec
TI  - Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer 
      Progression.
PG  - 391-6
AB  - BACKGROUND/AIM: Up-regulation of caveolin (CAV)-1 is associated with aggressive 
      prostate cancer. Recently, it has been inferred that CAV2, a co-factor sub-type 
      of CAV1, cross-talks with CAV1 and promotes tumor growth. We previously reported 
      that plasma CAV1 levels are elevated in patients with castration-resistant 
      prostate cancer (CRPC), but not in hormone-sensitive prostate cancer (non-CRPC), 
      implying that CAV1 may be a therapeutic target for CRPC. However, a correlation 
      of CAV1 and CAV2 expression in PC has not yet been reported. Herein, we analyzed 
      associations between PC progression and plasma CAV1 and -2 in Japanese men, and 
      expression of CAV1 and -2 in PC3 (CRPC) and LNCaP (non-CRPC) cell lines. 
      MATERIALS AND METHODS: We investigated plasma samples from 36 patients with CRPC 
      and 22 with non-CRPC. We used enzyme-linked immunosorbent assay (ELISA) to 
      determine plasma levels of CAV1 and -2, and examined correlations with 
      clinicopathological characteristics such as Gleason grade and clinical T stage. 
      Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
      was used to evaluate CAV1 and CAV2 mRNA in PC cell lines. We also introduced 
      CAV1- and CAV2-specific small interfering (siRNA) into PC3 cells to knock-down 
      (KD) both molecules, and examined its influence on the expression of these genes 
      between PC3 CAV1 and -2 KD cells and control cells. RESULTS: Plasma CAV1 and -2 
      levels in patients with CRPC were significantly higher than in those with 
      non-CRPC (CAV1, p=0.003; CAV2, p<0.001). Plasma levels of CAV1 and -2 were 
      significantly correlated (p<0.001). However, we did not find any significant 
      relationship between CAV1 or CAV2 expression and clinicopathological factors. 
      ELISA and real-time qRT-PCR showed that both proteins and mRNAs in PC3 cells were 
      significantly over-expressed compared to LNCaP cells (p<0.001). In PC3 CAV1 KD 
      cells, expression of CAV2 was suppressed and confirmed the linkage of CAV2 KD and 
      suppression of CAV1 expression. CONCLUSION: There was a significant correlation 
      between plasma CAV-1 and -2 levels and progression of PC. CAV1 and -2 were highly 
      expressed in the PC3 compared to the LNCaP cell line. Our findings support the 
      potential of these molecules as therapeutic targets for CRPC.
CI  - Copyright(c) 2015, International Institute of Anticancer Research (Dr. John G. 
      Delinasios), All rights reserved.
FAU - Sugie, Satoru
AU  - Sugie S
AD  - Department of Urology, Faculty of Medicine, University of Miyazaki, Kiyotake-cho, 
      Miyazaki, Japan.
FAU - Mukai, Shoichiro
AU  - Mukai S
AD  - Department of Urology, Faculty of Medicine, University of Miyazaki, Kiyotake-cho, 
      Miyazaki, Japan syoichiro_mukai@med.miyazaki-u.ac.jp.
FAU - Yamasaki, Koji
AU  - Yamasaki K
AD  - Department of Urology, Faculty of Medicine, University of Miyazaki, Kiyotake-cho, 
      Miyazaki, Japan.
FAU - Kamibeppu, Toyoharu
AU  - Kamibeppu T
AD  - Department of Urology, Faculty of Medicine, University of Miyazaki, Kiyotake-cho, 
      Miyazaki, Japan.
FAU - Tsukino, Hiromasa
AU  - Tsukino H
AD  - Department of Urology, Faculty of Medicine, University of Miyazaki, Kiyotake-cho, 
      Miyazaki, Japan.
FAU - Kamoto, Toshiyuki
AU  - Kamoto T
AD  - Department of Urology, Faculty of Medicine, University of Miyazaki, Kiyotake-cho, 
      Miyazaki, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Cancer Genomics Proteomics
JT  - Cancer genomics & proteomics
JID - 101188791
RN  - 0 (CAV1 protein, human)
RN  - 0 (CAV2 protein, human)
RN  - 0 (Caveolin 1)
RN  - 0 (Caveolin 2)
SB  - IM
MH  - Aged
MH  - Caveolin 1/*blood
MH  - Caveolin 2/*blood
MH  - Cell Line, Tumor
MH  - Disease Progression
MH  - Enzyme-Linked Immunosorbent Assay
MH  - *Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prostatic Neoplasms/*blood/pathology
MH  - Prostatic Neoplasms, Castration-Resistant/*blood/pathology
MH  - Retrospective Studies
MH  - Up-Regulation
OTO - NOTNLM
OT  - Caveolin-1
OT  - caveolin-2
OT  - prostate cancer progression
EDAT- 2015/11/07 06:00
MHDA- 2016/09/13 06:00
CRDT- 2015/11/07 06:00
PHST- 2015/11/07 06:00 [entrez]
PHST- 2015/11/07 06:00 [pubmed]
PHST- 2016/09/13 06:00 [medline]
AID - 12/6/391 [pii]
PST - ppublish
SO  - Cancer Genomics Proteomics. 2015 Nov-Dec;12(6):391-6.